HDAC2 regulates chromatin plasticity and enhances DNA vulnerability
about
Raloxifene and desmethylarzoxifene block estrogen-induced malignant transformation of human breast epithelial cellsAuto-acetylation stabilizes p300 in cardiac myocytes during acute oxidative stress, promoting STAT3 accumulation and cell survivalThe therapeutic potential of class I selective histone deacetylase inhibitors in ovarian cancerHistone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions.The clinical development of histone deacetylase inhibitors as targeted anticancer drugs.HDAC2 attenuates TRAIL-induced apoptosis of pancreatic cancer cells.Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer--overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression.Histone deacetylase inhibition redistributes topoisomerase IIβ from heterochromatin to euchromatinA phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancerRational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancerProtein-Protein Interactions of Viroporins in Coronaviruses and Paramyxoviruses: New Targets for Antivirals?HDAC5 is required for maintenance of pericentric heterochromatin, and controls cell-cycle progression and survival of human cancer cells.Class I histone deacetylase activity is required for proliferation of renal epithelial cells.Histone deacetylase regulation of ATM-mediated DNA damage signaling.Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker.Inhibitor of growth-4 mediates chromatin modification and has a suppressive effect on tumorigenesis and innate immunity.Developing histone deacetylase inhibitors in the therapeutic armamentarium of pancreatic adenocarcinoma.Valproic acid for the treatment of malignant gliomas: review of the preclinical rationale and published clinical results.Role of histone deacetylase 2 in epigenetics and cellular senescence: implications in lung inflammaging and COPDHDAC inhibitor-based therapies: can we interpret the code?A phase II study of SB939, a novel pan-histone deacetylase inhibitor, in patients with translocation-associated recurrent/metastatic sarcomas-NCIC-CTG IND 200†.Epigenetic modulation with histone deacetylase inhibitors in combination with immunotherapy.Processing of DNA double strand breaks by alternative non-homologous end-joining in hyperacetylated chromatinCombination of HDAC and topoisomerase inhibitors in small cell lung cancer.Changes in DNA Methylation and Chromatin Structure of Pro-inflammatory Cytokines Stimulated by LPS in Broiler Peripheral Blood Mononuclear Cells.Alterations of Nuclear Architecture and Epigenetic Signatures during African Swine Fever Virus Infection.Distinct and redundant functions of histone deacetylases HDAC1 and HDAC2 in proliferation and tumorigenesis.Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi.
P2860
Q28478183-A9E85C95-ADB5-4B40-B564-0BB6D88BA9D0Q28577251-7FCADEF8-79AA-4714-AD96-1B530692C961Q33659166-BB964979-3A0C-4D60-AF55-D3C3818D69D3Q33705588-842C6C40-65BF-42D4-AACC-51EBED32C070Q33829390-7840325E-6A6B-42EB-8513-4A845CF50C9AQ33842416-524F466A-F250-47ED-BF75-08F837BC2986Q34693969-8C885995-85AC-49D4-A10A-344EAE489247Q35015901-011EF94C-E037-4DDE-8581-90E75158FFF9Q35034708-9150BD43-141A-4786-A174-ECBD8EA468F3Q35079955-B27C1EF5-3BEA-4952-87ED-2DEB129ECCB3Q35808644-859C9A7D-2288-44BE-BC7F-874755CCD0DBQ36028506-BB5AE97D-ABC4-4078-9740-38A6456A5672Q37093664-4531147B-0B0B-49BA-8E56-EA89702C248CQ37291739-1F4FC593-A3D4-4DFA-8E32-B64C1B601C59Q37400592-D0844DA6-B478-4FD6-B93C-09459EDF2BCCQ37942489-E41AF8D1-D4AA-4A28-A29D-2F3140BCBF17Q38012499-67C7B3DC-1E66-4C91-8FAB-065D41B0DE4CQ38016227-20519C15-0215-4507-BADC-0109ED02CF62Q38030311-C2002BE3-957B-429C-8F59-C6C854576807Q38058971-D3A2FDB4-71BF-4A48-B179-0FABCCEB83B6Q38336253-9D2D67AF-43EC-4B95-9C0B-E1DB979CFF96Q38537768-E4B63D55-C21C-4D7F-89A3-9C4BC8C04C40Q39293918-091B5185-6367-4241-B19F-9DCF5EE7CE9FQ39375125-57E294F5-AC74-4FD9-8196-33BB2F32A236Q39905649-E470D4AA-A98B-470D-A965-6A608DE3D450Q40138443-D0286B70-BF92-479D-8101-64602A1B7DE4Q42757408-A187D82E-45A5-418F-A6D5-3A89E28816C0Q52590685-8E2FC3CC-D607-4AB2-9B0F-906392E7CB45
P2860
HDAC2 regulates chromatin plasticity and enhances DNA vulnerability
description
2009 nî lūn-bûn
@nan
2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
HDAC2 regulates chromatin plasticity and enhances DNA vulnerability
@ast
HDAC2 regulates chromatin plasticity and enhances DNA vulnerability
@en
HDAC2 regulates chromatin plasticity and enhances DNA vulnerability
@en-gb
HDAC2 regulates chromatin plasticity and enhances DNA vulnerability
@nl
type
label
HDAC2 regulates chromatin plasticity and enhances DNA vulnerability
@ast
HDAC2 regulates chromatin plasticity and enhances DNA vulnerability
@en
HDAC2 regulates chromatin plasticity and enhances DNA vulnerability
@en-gb
HDAC2 regulates chromatin plasticity and enhances DNA vulnerability
@nl
prefLabel
HDAC2 regulates chromatin plasticity and enhances DNA vulnerability
@ast
HDAC2 regulates chromatin plasticity and enhances DNA vulnerability
@en
HDAC2 regulates chromatin plasticity and enhances DNA vulnerability
@en-gb
HDAC2 regulates chromatin plasticity and enhances DNA vulnerability
@nl
P2093
P1476
HDAC2 regulates chromatin plasticity and enhances DNA vulnerability
@en
P2093
Dawn R Morelli
Douglas C Marchion
Elona Bicaku
Joel G Turner
Morgen L Schmitt
Pamela N Munster
P304
P356
10.1158/1535-7163.MCT-08-0985
P407
P577
2009-04-01T00:00:00Z